This cluster describes a convergent methodological trend in human genetics: the use of large-scale biobank data (UK Biobank, FinnGen, Million Veteran Program, Estonian Biobank, MoBa) to systematically generate and validate causal gene-trait relationships, which are then computationally prioritized as drug development candidates. Two complementary discovery engines anchor this trend—population-scale Mendelian Randomization (leveraging eQTLGen, GTEx, deCODE, ARIC, and Fenland as molecular proxies for target modulation across 2,003 phenotypes) and exome-wide/rare-variant burden analyses tied to rich, multi-organ MRI phenotyping (596 quantitative traits, yielding 224 gene-based burden associations and 107 variant-level associations, aided by AlphaMissense functional annotation). Both pipelines converge on the same downstream goal: nominating gene-trait pairs with genuine causal evidence, cross-validating them against OMIM, mouse knockout data, and rare variant burden studies, and feeding the results into a machine-learning Predictive Ranking Model trained on ChEMBL 34 approved-target annotations to forecast clinical translatability and likely indication—with results disseminated through the CIPHER platform.
A second, mechanistically distinct thread addresses parent-of-origin effects, reframing genomic imprinting and parental-conflict biology as an underexplored contributor to complex trait architecture. Novel statistical inference of allele parent-of-origin—without requiring parental genomes—is achieved through X chromosome data, mitochondrial data, interchromosomal phasing, and sex-specific crossover patterns in siblings, applied to over 100,000 UK Biobank participants and replicated in independent cohorts (Estonian Biobank, MoBa). This reveals opposing parental influences on growth and metabolic traits (height, IGF1, type 2 diabetes), lending empirical support to the parental conflict hypothesis of resource allocation.
Together, these threads reflect a broader macro-trend: triangulating multiple layers of genetic evidence (common-variant MR, rare-variant burden, imprinting/parent-of-origin signals, imaging-derived endophenotypes, and multi-omic proxies) to build higher-confidence, mechanistically interpretable causal maps of human phenotypes. The explicit coupling of causal discovery with predictive modeling of druggability signals a maturation of genetics-driven target discovery—moving from association to actionable, clinically indexed pharmaceutical development pipelines, while parent-of-origin analyses add a layer of regulatory nuance (imprinting-aware interpretation) that could refine which targets and mechanisms are prioritized for therapeutic intervention.